NAD+ therapy is the most common adjunct we use alongside the wolverine stack
Not for pregnant or breastfeeding individuals, minors, or any clinical dosing
Mild side effects may include dryness, flaking, redness, tightness, or sensitivity, especially in the first 2-4 weeks
Genetic factors affecting receptor expression or downstream signaling may limit effectiveness
That is the proposed reason it does not raise IGF-1 levels or impair insulin sensitivity in animal work, in contrast to full-length growth hormone
Researchers planning a cagrilintide + semaglutide protocol generally choose one of two formats: a pre-blended vial that delivers both compounds in a single weekly injection, or two separate vials titrated independently